Skip to main content

Advertisement

SpringerLink
Log in

Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies

  • T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Enteropathy-associated T-cell lymphoma (EATL) is a rare non-Hodgkin lymphoma of T-cell origin. The recent 2008 World Health Organization classification of hematologic malignancies distinguishes between two types of EATL. The disease is associated with celiac disease, particularly with its late, adult onset. Currently, there are no standardized diagnostic or treatment protocols for EATL, mostly because of its rarity. Historically, the patients have been treated with anthracycline-based chemotherapy with or without surgery. The outcome of patients with EATL treated with these approaches is poor. The reported death rates in the biggest studies are approximately 80–84%, with median progression-free survival (PFS) of 3.4–6.0 months and overall survival of 7.1–10.0 months. The 5-year PFS ranged from 3.2% to 18% and OS from 19.7% to 20%. The results of a novel induction regimen with ifosfamide, etoposide, and epirubicin alternating with intermediate-dose methotrexate followed by autologous stem cell transplantation (ASCT) are more promising, with a 5-year PFS of 52% and OS of 60%. The alternative approach, with a more common induction with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone followed by ASCT has also delivered promising results, with a 3-year PFS of 52% and OS of 47%. This review summarizes recently published data on epidemiology and clinical features, as well as standard and novel treatments including high-dose chemotherapy with ASCT and their outcome in EATL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.

    Google Scholar 

  2. Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795–803.

    PubMed  CAS  Google Scholar 

  3. Domizio P, Owen RA, Shepherd NA, Talbot IC, Norton AJ. Primary lymphoma of the small intestine. A clinicopathological study of 119 cases. Am J Surg Pathol. 1993;17:429–42.

    Article  PubMed  CAS  Google Scholar 

  4. Isaacson PG, Du MQ. Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol. 2005;205:255–74.

    Article  PubMed  CAS  Google Scholar 

  5. Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA. 2002;287:1413.

    Article  PubMed  Google Scholar 

  6. Diamanti A, Colistro F, Calce A, et al. Clinical value of immunoglobulin A antitransglutaminase assay in the diagnosis of celiac disease. Pediatrics. 2006;118:e1696–700.

    Article  PubMed  Google Scholar 

  7. Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357:1731–43.

    Article  PubMed  CAS  Google Scholar 

  8. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French coeliac disease study group. Lancet. 2000;356:203–8.

    Article  PubMed  CAS  Google Scholar 

  9. Isaacson PG. Malignant histiocytosis of the intestine. J Pathol. 1985;147(3):227–8.

    Article  PubMed  CAS  Google Scholar 

  10. Howdle PD, Jalal PK, Holmes GK, Houlston RS. Primary small-bowel malignancy in the UK and its association with coeliac disease. QJM. 2003;96:345–53.

    Article  PubMed  CAS  Google Scholar 

  11. Salmi TT, Collin P, Korponay-Szabo IR, et al. Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits. Gut. 2006;55:1746–53.

    Article  PubMed  CAS  Google Scholar 

  12. Deleeuw RJ, Zettl A, Klinker E, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007;132:1902–11.

    Article  PubMed  CAS  Google Scholar 

  13. Dube C, Rostom A, Sy R, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology. 2005;128:S57–67.

    Article  PubMed  Google Scholar 

  14. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163:286–92.

    Article  PubMed  Google Scholar 

  15. Verbeek WH, Van De Water JM, Al-Toma A, Oudejans JJ, Mulder CJ, Coupe VM. Incidence of enteropathy-associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. Scand J Gastroenterol. 2008;43:1322–8.

    Article  PubMed  Google Scholar 

  16. Daum S, Cellier C, Mulder CJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol. 2005;19:413–24.

    Article  PubMed  Google Scholar 

  17. Al-Toma A, Verbeek WH, Hadithi M, von Blomberg BM, Mulder CJ. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut. 2007;56:1373–8.

    Article  PubMed  CAS  Google Scholar 

  18. Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8 + CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol. 1998;153:1483–90.

    Article  PubMed  CAS  Google Scholar 

  19. Chott A, Vesely M, Simonitsch I, Mosberger I, Hanak H. Classification of intestinal T-cell neoplasms and their differential diagnosis. Am J Clin Pathol. 1999;111:S68–74.

    PubMed  CAS  Google Scholar 

  20. Spencer J, Cerf-Bensussan N, Jarry A, et al. Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes. Am J Pathol. 1988;132:1–5.

    PubMed  CAS  Google Scholar 

  21. Wright DH. Enteropathy associated T cell lymphoma. Cancer Surv. 1997;30:249–61.

    PubMed  CAS  Google Scholar 

  22. Murray A, Cuevas EC, Jones DB, Wright DH. Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma. Am J Pathol. 1995;146:509–19.

    PubMed  CAS  Google Scholar 

  23. Howell WM, Leung ST, Jones DB, et al. HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Hum Immunol. 1995;43:29–37.

    Article  PubMed  CAS  Google Scholar 

  24. Zettl A, Ott G, Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol. 2002;161:1635–45.

    Article  PubMed  CAS  Google Scholar 

  25. •• Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664–3670. The Scotland and Newcastle Lymphoma Group (SNLG) performed a detailed, population-based evaluation of patients with EATL registered with the group between 1994 and 1998. Data obtained included patient demographics, details on baseline evaluations, treatment, and patient outcomes. They also presented the results of novel first-line treatment with ifosfamide, etoposide, and epirubicin with intermediate-dose methotrexate followed by ASCT.

    Article  PubMed  CAS  Google Scholar 

  26. • D’Amore F, Lauritzen G, Jantunen E, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs) - overall and subtype specific results of a phase II study from the Nordic Lymphoma Group. 14th Congress of the EHA. 2009. This is an interim analysis of a big, multicenter, prospective study on dose-dense induction with CHOEP-14 followed by ASCT in patients with PTCL. Among the 160 patients included were 21 patients with EATL.

  27. •• Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood. 2011;118:148–155. The International T-cell Lymphoma Project (ITLP) studied a cohort of 62 EATL patients among 1,153 patients with PTCL from 22 centers worldwide, diagnosed between 1990 and 2002. Clinical correlation and survival analyses were performed.

    Article  PubMed  CAS  Google Scholar 

  28. Berman EL, Zauber NP, Rickert RR, Diss TC, Isaacson PG. Enteropathy-associated T cell lymphoma with brain involvement. J Clin Gastroenterol. 1998;26:337–41.

    Article  PubMed  CAS  Google Scholar 

  29. Tutt AN, Brada M, Sampson SA. Enteropathy associated T cell lymphoma presenting as an isolated CNS lymphoma three years after diagnosis of coeliac disease: T cell receptor polymerase chain reaction studies failed to show the original enteropathy to be a clonal disorder. Gut. 1997;40:801.

    Article  PubMed  CAS  Google Scholar 

  30. Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin’s lymphoma: a multicenter prospective clinical study from the German study group on intestinal non-Hodgkin’s Lymphoma. J Clin Oncol. 2003;21:2740–6.

    Article  PubMed  Google Scholar 

  31. Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood. 2007;109:2243–9.

    Article  PubMed  CAS  Google Scholar 

  32. O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27:4357–64.

    Article  PubMed  Google Scholar 

  33. Piekarz R, Wright J, Frye R, Allen SL, Craig M, Geskin L. Results of a phase 2 NCI multicentre study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood (ASH Annual Meeting Abstracts). 2008;112:1567.

    Google Scholar 

  34. Dueck GS, Chua N, Prasad A, Stewart D, White D, van der Jagt R. Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases. J Clin Oncol (ASCO Meeting Abstracts). 2009;27:8524.

    Google Scholar 

  35. Furman RR, Gore L, Ravandi F, Hoelzer D. Forodesine IV (Bcx 1777) is clinically active in relapsed/refractory T-cell leukemia: Results of a phase II study (interim report). Blood (ASH Annual Meeting Abstracts). 2006;108:1851.

    Google Scholar 

  36. Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998;9:1351–3.

    Article  PubMed  CAS  Google Scholar 

  37. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185–7.

    Article  PubMed  CAS  Google Scholar 

  38. • Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–113. This multicenter, prospective trial assessed the role of ASCT in consolidation in patients with PTCL in first remission after the standard treatment with CHOP.

    Article  PubMed  CAS  Google Scholar 

  39. Mounier N, Gisselbrecht C, Briere J, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol. 2004;15:1790–7.

    Article  PubMed  CAS  Google Scholar 

  40. Okuda M, Nomura J, Tateno H, Kameoka J, Sasaki T. CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation. Intern Med. 2002;41:734–7.

    Article  PubMed  Google Scholar 

  41. Rongey C, Micallef I, Smyrk T, Murray J. Successful treatment of enteropathy-associated T cell lymphoma with autologous stem cell transplant. Dig Dis Sci. 2006;51:1082–6.

    Article  PubMed  Google Scholar 

  42. Al-Toma A, Verbeek WH, Visser OJ, et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis. 2007;39:634–41.

    Article  PubMed  CAS  Google Scholar 

  43. Nickelsen M, Ziepert M, Zeynalova S, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol. 2009;20:1977–84.

    Article  PubMed  CAS  Google Scholar 

  44. Goerres MS, Meijer JW, Wahab PJ, et al. Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment Pharmacol Ther. 2003;18:487–94.

    Article  PubMed  CAS  Google Scholar 

  45. Bernstein EF, Whitington PF. Successful treatment of atypical sprue in an infant with cyclosporine. Gastroenterology. 1988;95:199–204.

    PubMed  CAS  Google Scholar 

  46. Wahab PJ, Crusius JB, Meijer JW, Uil JJ, Mulder CJ. Cyclosporin in the treatment of adults with refractory coeliac disease–an open pilot study. Aliment Pharmacol Ther. 2000;14:767–74.

    Article  PubMed  CAS  Google Scholar 

  47. Mulder CJ, Wahab PJ, Meijer JW, Metselaar E. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur J Gastroenterol Hepatol. 2001;13:1183–8.

    Article  PubMed  CAS  Google Scholar 

  48. Al-Toma A, Goerres MS, Meijer JW, et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol. 2006;4:1322–7. quiz 1300.

    Article  PubMed  CAS  Google Scholar 

  49. Mallant M, Hadithi M, Al-Toma AB, et al. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J Gastroenterol. 2007;13:1696–700.

    PubMed  Google Scholar 

  50. Hadithi M, Mallant M, Oudejans J, van Waesberghe JH, Mulder CJ, Comans EF. 18 F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med. 2006;47:1622–7.

    PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Haematological Sciences, Newcastle University, Leech Building, Medical School, Newcastle upon Tyne, NE2 4HH, UK

    Michal K. Sieniawski & Anne L. Lennard

Authors
  1. Michal K. Sieniawski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne L. Lennard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michal K. Sieniawski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sieniawski, M.K., Lennard, A.L. Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies. Curr Hematol Malig Rep 6, 231–240 (2011). https://doi.org/10.1007/s11899-011-0097-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-011-0097-7

Keywords

Search

Navigation